Should the UK-US medicine pricing agreement have an independent audit?
The UK-US pharmaceutical pricing arrangement, finalised in April 2026, requires the UK to increase NHS spending on new medicines from 0.3% to 0.6% of GDP by 2036 and raise net prices by 25% from April 2026. It secures zero US tariffs on UK pharmaceutical exports for three years. In mid-September 2026 six parliamentary committees wrote to the National Audit Office requesting a rapid investigation into its costs and value for money after the government withheld a full impact assessment despite an estimated £1 billion short-term cost to the NHS.
0 Opinions
Weigh in on the debate.